Literature DB >> 19081161

Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.

Ikuo Sekine1, Hiroshi Nokihara, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura.   

Abstract

The purpose of this study was to identify the risk factors for skeletal-related events (SREs) in patients with advanced non-small cell lung cancer (NSCLC). SREs were defined as pathologic fractures, spinal cord compression, requirement for radiation therapy, other radiological intervention, or surgery to the bone, and hypercalcemia of malignancy. Time-to-the first SRE and SRE-free survival, and their associations with the patient characteristics were evaluated retrospectively in 642 patients with metastatic NSCLC who received systemic chemotherapy. A total of 118 (18.4%) patients developed SREs during or after the initial chemotherapy. Of these, 107 required radiotherapy to the bone, 5 developed hypercalcemia of malignancy, 3 developed compression fracture of the vertebrae, 2 required surgical treatment of the bone, and 1 underwent radiofrequency ablation therapy to the bone. The first SRE occurred within 12 months in 80 (67.8%) of the 107 patients. The results of multivariate analysis revealed that male sex, performance status (PS) of 2-3 and multiple bone metastases were risk factors for the first SRE, with hazard ratios (HRs) (95% confidence interval [CI]) to the reference of 1.44 (0.98-2.11), 2.21 (0.97-5.03) and 4.43 (2.91-6.76), respectively. SRE-free survival showed a similar trend. The HRs (CI) of male sex, PS of 2 and multiple bone metastases were 1.64 (1.30-2.06), 3.72 (2.31-5.98) and 1.80 (1.40-2.31), respectively. In conclusion, the presence of multiple bone metastases was significantly associated with the development of SRE in patients with advanced NSCLC treated by systemic chemotherapy. Male sex and poor performance status may be additional risk factors for the development of SREs in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081161     DOI: 10.1016/j.lungcan.2008.10.026

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

1.  Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.

Authors:  Arife Ulas; Ahmet Bilici; Ayse Durnali; Saadet Tokluoglu; Sema Akinci; Kamile Silay; Berna Oksuzoglu; Necati Alkis
Journal:  Tumour Biol       Date:  2015-08-15

2.  Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer.

Authors:  Gustavo Telles da Silva; Anke Bergmann; Luiz Claudio Santos Thuler
Journal:  Support Care Cancer       Date:  2015-07-05       Impact factor: 3.603

Review 3.  Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies.

Authors:  Chiara D'Antonio; Antonio Passaro; Bruno Gori; Ester Del Signore; Maria Rita Migliorino; Serena Ricciardi; Alberto Fulvi; Filippo de Marinis
Journal:  Ther Adv Med Oncol       Date:  2014-05       Impact factor: 8.168

4.  Association between bone scan index and activities of daily living in patients with advanced non-small cell lung cancer.

Authors:  Ikuno Ito; Kimiteru Ito; Shinichi Takahashi; Mitsuko Horibe; Rui Karita; Chika Nishizaka; Takako Nagai; Kohei Hamada; Hiroyuki Sato; Naoko Shindo
Journal:  Support Care Cancer       Date:  2017-01-20       Impact factor: 3.603

5.  Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.

Authors:  Hirotaka Miyashita; Christina Cruz; Cardinale Smith
Journal:  Support Care Cancer       Date:  2020-08-03       Impact factor: 3.603

6.  Lung cancer with bone metastases in the United States: an analysis from the Surveillance, Epidemiologic, and End Results database.

Authors:  Wangmi Liu; Jiayan Wu
Journal:  Clin Exp Metastasis       Date:  2018-10-19       Impact factor: 5.150

Review 7.  Bone matters in lung cancer.

Authors:  T Brodowicz; K O'Byrne; C Manegold
Journal:  Ann Oncol       Date:  2012-02-22       Impact factor: 32.976

8.  Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.

Authors:  Go Saito; Takahiro Ebata; Tsukasa Ishiwata; Shunichiro Iwasawa; Ichiro Yoshino; Yuichi Takiguchi; Koichiro Tatsumi
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.359

9.  Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.

Authors:  Haruyasu Murakami; Takeharu Yamanaka; Takashi Seto; Kenji Sugio; Isamu Okamoto; Toshiyuki Sawa; Tomonori Hirashima; Koji Takeda; Shinji Atagi; Masahiro Fukuoka; Yoichi Nakanishi; Kazuhiko Nakagawa; Nobuyuki Yamamoto
Journal:  Cancer Sci       Date:  2014-07-12       Impact factor: 6.716

10.  Risk factors for bone metastasis in patients with primary lung cancer: study protocol for a systematic review.

Authors:  Yu-Jie Niu; Yin-Tian Wen; Wei-Wei Shen; Lin Deng; Li-Li Liu; He-Long Zhang
Journal:  BMJ Open       Date:  2014-07-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.